• Tofacitinib: A Systems View of RA Macrophages

  2026-09-11

  Tofacitinib and CP-690550 are examined as mechanistic probes of rheumatoid arthritis macrophage dysfunction, not merely as JAK inhibitors. This article connects cytokine signaling blockade with mitochondrial readouts and provides an assay framework for distinguishing direct pathway effects from broader immune reprogramming.

• EZ Cap EGFP mRNA 5-moUTP Workflow Guide

  2026-09-10

  Build reproducible reporter assays with Cap1-capped, 5-methoxyuridine-modified EGFP mRNA and an optimized poly(A) tail. This practical guide connects transfection quality control, translation efficiency testing, innate-immune monitoring, and in vivo fluorescence workflows.

• Perospirone Inhibits Coronary Vascular Kv Channels

  2026-09-10

  A 2025 Journal of Applied Toxicology study identifies a previously unrecognized, concentration-dependent inhibition of voltage-gated K+ currents by perospirone in freshly isolated rabbit coronary arterial smooth muscle cells. The pharmacological profile implicates Kv1.5 channels and provides a mechanistic basis for evaluating vascular ion-channel effects alongside the compound’s established serotonergic and dopaminergic actions.

• MK-8745: Reading Aurora A Dependency

  2026-09-09

  MK-8745 is a potent, selective Aurora A inhibitor for dissecting mitotic failure, p53-contextual apoptosis, and tumor dependency. This article translates retinoblastoma evidence into a practical framework for choosing assays and interpreting cell-cycle, apoptosis, and xenograft results.

• GI 254023X: ADAM10 Inhibition Workflows

  2026-09-09

  GI 254023X is a selective ADAM10 inhibitor for connecting sheddase activity with Notch1 signaling, leukemic-cell phenotypes, and endothelial barrier protection. This practical guide combines dose planning, orthogonal readouts, comparative interpretation, and troubleshooting for translational cell and vascular models.

• SAR131675: VEGFR-3 Inhibitor Workflows

  2026-09-08

  Build reproducible VEGFR-3 target-engagement, lymphangiogenesis, angiogenesis, and hepatic fibrosis assays with SAR131675. This workflow emphasizes fresh compound handling, orthogonal controls, and the VEGFC–VEGFR-3 axis revealed in a recent NASH fibrosis study.

• Protease Inhibitor Cocktail EDTA-Free Guide

  2026-09-08

  Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) helps limit endogenous proteolysis during protein extraction and sample preparation while avoiding EDTA-related effects on divalent-cation-sensitive workflows. It is suitable for lysates, Western blotting, co-immunoprecipitation, and phosphorylation-related assays, but it should not replace cold handling, rapid processing, or assay-specific compatibility testing.

• High-Throughput Surrogate Model for BBB Permeability

  2026-09-07

  The 2025 reference study develops a Transwell blood-brain barrier surrogate that combines LLC-PK1-MOCK and LLC-PK1-MDR1 cells with permeability, efflux, recovery, and lysosomal-trapping measurements. Its correlation with unbound brain distribution and correction of low-recovery compounds support a more mechanistic and efficient approach to early CNS drug screening.

• RepSox for iPSC and Platelet Research

  2026-09-07

  RepSox provides a selective way to interrogate ALK5-dependent TGF-β signaling in reprogramming, differentiation, and tumor biology workflows. Used with appropriate controls, it can help researchers separate pathway effects from the medium, cell-density, and maturation variables that govern iPSC-derived megakaryocyte and platelet production.

• Meropenem in Carbapenem Resistance Workflows

  2026-09-05

  Meropenem supports reproducible susceptibility testing, resistance-mechanism profiling, and Gram-negative infection model design. This guide connects β-lactam pharmacology with plasmid-focused surveillance, formulation comparisons, and practical troubleshooting for carbapenem-resistant bacterial infections.

• CCK-8 Workflow for CRC Cell Viability Studies

  2026-09-04

  Build a sensitive, low-friction CCK-8 workflow for measuring colorectal cancer cell proliferation, viability, and treatment response. This guide connects WST-8 assay design with the SYT8–SETD1A–H3K4me3 findings and shows how to improve controls, dynamic range, and interpretation.

• Uridine, Trisodium Salt in PRINT Workflows

  2026-09-04

  Uridine, Trisodium Salt supports controlled RNA metabolism, cell-state, and vascular assay design around RNA-mediated genome engineering. This guide distinguishes its role as a cellular precursor from polymerase-ready nucleotides and translates PRINT findings into practical controls, preparation steps, and troubleshooting decisions.

• Autophagy–Liver Metastasis Signature in CRC

  2026-09-03

  Bai et al. integrated bulk and single-cell transcriptomic data to develop and validate a six-gene prognostic signature linking autophagy, liver metastasis, and immune dysfunction in colorectal cancer. The framework may help stratify prognosis and treatment response while identifying macrophage and CD8+ T-cell states associated with an immunosuppressive tumor microenvironment.

• Troglitazone: PPARγ Agonist Workflows

  2026-09-03

  Build reproducible Troglitazone workflows for PPARγ signaling, metabolic assays, macrophage phenotyping, and renal carcinoma studies. The guide separates established product properties from practical starting conditions and explains how SPP1-focused tumor-myeloid research can sharpen assay design without mistaking pathway modulation for direct SPP1 inhibition.

• MK-8745: Aurora A Inhibitor Workflows

  2026-09-02

  Build a practical Aurora A inhibition workflow around MK-8745, from formulation and cell-cycle profiling to apoptosis and xenograft studies. The approach translates retinoblastoma evidence into controlled, genetically informed assays for cancer biology and translational research.

8101 records 1/541 page Next 12345 下5页 Last page